Labthermics Technologies, Inc. is a medical therapy products company dedicated to improving cancer treatment. Over the past ten years, the Company has invested in hyperthermia cancer research, resulting in a series of unique cancer therapy products -- the first of which received FDA approval in September 1989. During the past ten years, Labthermics has grown from a small R&D company to a fully faceted corporation with FDA approved products.
Labthermics' first commercial therapy product, the SONOTHERM 1000, is the most technologically advanced hyperthermia device available. Since the SONOTHERM can treat larger and deeper tumors, it can effectively treat three times as many patients as competing hyperthermia systems. Its unique multi-sectored therapy applicator design and adaptive control system enable it to shape the energy field to match the tumor size and shape, which results in more effective heating than that provided by competing systems. It is the only FDA approved device for treatment of tumors to 8 cm depth and for treatment in conjunction with initial course radiotherapy. New products currently in FDA clinical trials, are the MICROTHERM® 1000 microwave therapy system (incorporating multi-element applicators and the same adaptive control system as the SONOTHERM 1000), and the INTERTHERM 100 RF interstitial applicator module (used with the SONOTHERM 1000). The Company's systems have had a significant impact on many cancer patients. The SONOTHERM 1000, prior to FDA approval, was utilized in clinical studies by 13 distinguished medical institutions, which treated approximately 200 patients during the clinical study period. The clinical results from the FDA trials for the system demonstrated that the SONOTHERM 1000 was safe and effective for combined use with radiotherapy in the treatment of solid surface, sub-surface and deep (to 8 cm) malignant tumors.
Research and Development
In recent years, Labthermics Technologies has received grants totaling $2.1 million dollars from the National Cancer Institute Small Business Innovative Research program. These grants were for thermal therapy R&D programs involving; microwave phased arrays to improve the penetration depth of microwave energy, ultrasound phased arrays to enable three-dimensional control of focused ultrasound fields, development of high frequency planar array transducers for hyperthermia, ultrasound phased arrays for surgical applications, and development of specialized applicators for breast cancer hyperthermia. Labthermics hardware and software designers have also designed and built custom computer controlled RF drive systems for the University of Arizona, University of Illinois, Indianapolis Center for Advanced Research, University of California San Francisco, and Mallinckrodt Institute of Radiology. Labthermics was the major subcontractor to Harvard University, Dana-Farber Cancer Institute for the development and testing of a custom digitally controlled 56-element fixed-focus ultrasonic therapy system for cancer research.
The multidisciplinary expertise demonstrated by the successful completion of these and other research programs, coupled with modern, well-equipped facilities, point to the unique capabilities and performance of LTI in the design, development, documentation, and testing of hardware and software systems.